Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total transaction of $1,667,397.05.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded up $1.50 during trading on Thursday, hitting $31.62. The company had a trading volume of 346,173 shares, compared to its average volume of 1,371,751. The company has a market cap of $1.82 billion, a P/E ratio of -14.08 and a beta of 0.48. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The business’s 50-day moving average is $27.04 and its 200 day moving average is $18.74.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Oppenheimer lifted their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Maxim Group upped their price target on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Finally, B. Riley Financial raised their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ACT Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $43,000. GoalVest Advisory LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter worth $59,000. Allworth Financial LP boosted its holdings in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after buying an additional 3,264 shares during the period. Farther Finance Advisors LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at $28,000. Finally, State of Wyoming grew its stake in Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 1,913 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.